Tretinoin/benzoyl peroxide, sold under the brand name Twyneo, is a fixed-dose combination medication used for the treatment of acne. It contains tretinoin, a vitamin A derivative, and benzoyl peroxide, an oxidizing agent. The U.S. Food and Drug Administration (FDA) approved this medication for use in July 2021. Historically, the co-formulation of these two active ingredients was avoided because benzoyl peroxide typically causes the oxidative degradation of tretinoin when stored together. To address this stability issue, Twyneo employs a silica-based sol-gel microencapsulation technology, which serves as a physical barrier that prevents the benzoyl peroxide from damaging the tretinoin within the vehicle.
References
External links "Tretinoin". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 5 July 2016. "Benzoyl peroxide". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 29 April 2021. Clinical trial number NCT03761784 for "A Study of S6G5T-3 in the Treatment of Acne Vulgaris" at ClinicalTrials.gov Clinical trial number NCT03761810 for "A Study of S6G5T 3 in the Treatment of Acne Vulgaris" at ClinicalTrials.gov
